Skip to main content

Vumerity (diroximel fumarate) Disease Interactions

There are 4 disease interactions with Vumerity (diroximel fumarate):

Moderate

Diroximel fumarate (applies to Vumerity) liver injury

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Clinically significant cases of liver injury have been reported in patients treated with dimethyl fumarate (which has the same active metabolite as diroximel fumarate) in the postmarketing setting. Signs and symptoms of liver injury, including elevation of serum aminotransferases to greater than 5-fold the upper limit of normal and elevation of total bilirubin to greater than 2-fold the upper limit of normal have been observed. These abnormalities resolved upon treatment discontinuation. Caution and monitoring is advised in patients with liver impairment, as no studies have been conducted in these patients. Obtain serum aminotransferase, alkaline phosphatase (ALP), and total bilirubin levels prior and during treatment. Discontinue therapy if liver injury is suspected.

Moderate

Diroximel fumarate (applies to Vumerity) lymphopenia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Lymphocytopenia, Infection - Bacterial/Fungal/Protozoal/Viral

Diroximel fumarate may decrease lymphocyte counts up to 30% during the first year of treatment. Neither diroximel fumarate nor dimethyl fumarate (same active metabolite) have been studied in patients with preexisting low lymphocyte counts. Caution and monitoring is advised in patients with low lymphocyte counts. Consider withholding treatment from patients with serious infections until resolution.

Moderate

Diroximel fumarate (applies to Vumerity) multiple sclerosis

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

There have been postmarketing reports of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus, in patients with MS treated with dimethyl fumarate (which has the same active metabolite as diroximel fumarate). Caution and monitoring is advised in patients with MS. Withhold treatment at the first sign or symptom of PML to perform an appropriate diagnosis.

Moderate

Diroximel fumarate (applies to Vumerity) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Due to an increase in the exposure of a major metabolite [2-hydroxyethyl succinimide (HES)], the use of diroximel fumarate is not recommended in patients with moderate or severe renal impairment.

Vumerity (diroximel fumarate) drug interactions

There are 318 drug interactions with Vumerity (diroximel fumarate)

Vumerity (diroximel fumarate) alcohol/food interactions

There are 2 alcohol/food interactions with Vumerity (diroximel fumarate)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.